Macrophage/monocyte Receptor for Nonenzymatically Glycosylated Protein is Upregulated by Cachectin/tumor Necrosis Factor

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1989 Dec 1

PMID 2556447

Citations 21

Authors

H Vlassara

L Moldawer

B Chan

Affiliations

Soon will be listed here.

Abstract

Proteins of extracellular matrix undergo over time multiple reactions with glucose to form advanced glycosylation endproducts (AGEs) which are highly active in protein crosslinking, and have been implicated in tissue damage associated with aging and diabetes. A macrophage/monocyte receptor for AGE moieties mediates the uptake of AGE-modified proteins by a process that also induces cachectin/tumor necrosis factor (TNF) and IL-1 secretion. Reasoning that cytokines might regulate this AGE-receptor system, we have evaluated the effect of cachectin/TNF, IL-1, and IFN-gamma on AGE-protein processing. We report that cachectin/TNF induced a severalfold enhancement of binding, endocytosis, and degradation of AGE-BSA by both murine peritoneal macrophages and human blood monocytes in vitro, and that cachectin/TNF enhanced the rate of disappearance of AGE-modified red blood cells in vivo. IL-1 and IFN-gamma alone did not increase AGE processing, but IFN-gamma consistently enhanced cachectin/TNF-induced changes in AGE-receptor kinetics. Similar effects were induced by AGE-BSA and FFI-BSA, a chemically synthesized AGE, when used as macrophage stimulants, possibly via cachectin/TNF induction. All upregulatory responses were blocked by anticachectin/TNF monoclonal antibody. These data suggest that AGE-induced cachectin/TNF, in addition to influencing tissue regeneration and remodelling, may also normally regulate the disposal of tissue damaging AGE-proteins through an autocrine upregulation.

Citing Articles

Effects of scavenger receptors-1 class A stimulation on macrophage morphology and highly modified advanced glycation end product-protein phagocytosis.

Hamasaki S, Kobori T, Yamazaki Y, Kitaura A, Niwa A, Nishinaka T Sci Rep. 2018; 8(1):5901.

PMID: 29651042 PMC: 5897562. DOI: 10.1038/s41598-018-24325-y.

Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products.

Milutinovic P, Englert J, Crum L, Mason N, Ramsgaard L, Enghild J PLoS One. 2014; 9(3):e88259.

PMID: 24642901 PMC: 3958346. DOI: 10.1371/journal.pone.0088259.

Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia.

Torreggiani M, Liu H, Wu J, Zheng F, Cai W, Striker G Am J Pathol. 2009; 175(4):1722-32.

PMID: 19779136 PMC: 2751567. DOI: 10.2353/ajpath.2009.090138.

Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression.

Cai W, He J, Zhu L, Chen X, Wallenstein S, Striker G Am J Pathol. 2007; 170(6):1893-902.

PMID: 17525257 PMC: 1899464. DOI: 10.2353/ajpath.2007.061281.

Macrophage function in alloxan diabetic mice: expression of adhesion molecules, generation of monokines and oxygen and NO radicals.

Ptak W, Klimek M, Bryniarski K, Ptak M, Majcher P Clin Exp Immunol. 1998; 114(1):13-8.

PMID: 9764597 PMC: 1905080. DOI: 10.1046/j.1365-2249.1998.00687.x.

References

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Bianco C, Eden A, COHN Z . The induction of macrophage spreading: role of coagulation factors and the complement system. J Exp Med. 1976; 144(6):1531-44. PMC: 2190471. DOI: 10.1084/jem.144.6.1531. View

Johnson Jr W, Mei B, COHN Z . The separation, long-term cultivation, and maturation of the human monocyte. J Exp Med. 1977; 146(6):1613-26. PMC: 2181917. DOI: 10.1084/jem.146.6.1613. View

Leibovich S, Polverini P, Shepard H, Wiseman D, Shively V, Nuseir N . Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature. 1987; 329(6140):630-2. DOI: 10.1038/329630a0. View

Tracey K, Wei H, Manogue K, Fong Y, Hesse D, Nguyen H . Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988; 167(3):1211-27. PMC: 2188883. DOI: 10.1084/jem.167.3.1211. View

Brownlee M, Cerami A, Vlassara H . Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318(20):1315-21. DOI: 10.1056/NEJM198805193182007. View

Vlassara H, Brownlee M, Manogue K, Dinarello C, Pasagian A . Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 1988; 240(4858):1546-8. DOI: 10.1126/science.3259727. View

Radoff S, Vlassara H, Cerami A . Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products. Arch Biochem Biophys. 1988; 263(2):418-23. DOI: 10.1016/0003-9861(88)90654-6. View

Vlassara H, Brownlee M, Cerami A . Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes. 1988; 37(4):456-61. DOI: 10.2337/diab.37.4.456. View

10.

Sherry B, Cerami A . Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol. 1988; 107(4):1269-77. PMC: 2115248. DOI: 10.1083/jcb.107.4.1269. View

11.

Brenner D, Ohara M, Angel P, Chojkier M, Karin M . Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature. 1989; 337(6208):661-3. DOI: 10.1038/337661a0. View

12.

Moldawer L, Marano M, Wei H, Fong Y, Silen M, Kuo G . Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J. 1989; 3(5):1637-43. DOI: 10.1096/fasebj.3.5.2784116. View

13.

Romero R, Manogue K, Mitchell M, Wu Y, Oyarzun E, Hobbins J . Infection and labor. IV. Cachectin-tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor. Am J Obstet Gynecol. 1989; 161(2):336-41. DOI: 10.1016/0002-9378(89)90515-2. View

14.

COHN Z, Benson B . THE DIFFERENTIATION OF MONONUCLEAR PHAGOCYTES. MORPHOLOGY, CYTOCHEMISTRY, AND BIOCHEMISTRY. J Exp Med. 1965; 121:153-70. PMC: 2137972. DOI: 10.1084/jem.121.1.153. View

15.

Fraker P, SPECK Jr J . Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978; 80(4):849-57. DOI: 10.1016/0006-291x(78)91322-0. View

16.

Gmelig-Meyling F, Waldmann T . Separation of human blood monocytes and lymphocytes on a continuous Percoll gradient. J Immunol Methods. 1980; 33(1):1-9. DOI: 10.1016/0022-1759(80)90077-0. View

17.

Wright S, Silverstein S . Tumor-promoting phorbol esters stimulate C3b and C3b' receptor-mediated phagocytosis in cultured human monocytes. J Exp Med. 1982; 156(4):1149-64. PMC: 2186805. DOI: 10.1084/jem.156.4.1149. View

18.

Pace J, RUSSELL S, Schreiber R, Altman A, Katz D . Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. Proc Natl Acad Sci U S A. 1983; 80(12):3782-6. PMC: 394136. DOI: 10.1073/pnas.80.12.3782. View

19.

Nathan C, Murray H, Wiebe M, Rubin B . Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983; 158(3):670-89. PMC: 2187114. DOI: 10.1084/jem.158.3.670. View

20.

Kohn R, Cerami A, Monnier V . Collagen aging in vitro by nonenzymatic glycosylation and browning. Diabetes. 1984; 33(1):57-9. DOI: 10.2337/diab.33.1.57. View